Antipsychotic use in older adults with Parkinson’s disease
Marras C, Kopp A, Qiu F, Lang AE, Sykora K, Shulman KI, Rochon PA. Mov Disord. 2007; 22(3):319-23.
Publications
Atypical antipsychotics and parkinsonism
Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand SL, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH. Arch Intern Med. 2005; 165(16):1882-8.
Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: a population-based cohort study in older adults
Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand SL, Rochon PA. J Am Geriatr Soc. 2005; 53(8):1374-9.
New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice
Shulman KI, Sykora K, Gill SS, Mamdani M, Anderson G, Marras C, Wodchis WP, Lee PE, Rochon P. Am J Geriatr Psychiatry. 2005; 13(4):299-304.
Atypical antipsychotic drugs and risk of ischaemic stroke: population-based retrospective cohort study
Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, Normand SL, Gurwitz JH, Marras C, Wodchis WP, Mamdani M. BMJ. 2005; 330(7489):445. Epub 2005 Jan 24.
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort
Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE; Parkinson Study Group. Neurology. 2005; 64(1):87-93.